STOCK TITAN

Ligand Announces 2025 Investor Day in New York City

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Positive)
Tags
Ligand Pharmaceuticals (NASDAQ: LGND) has announced plans to host an Investor Day event on December 9, 2025, at 10 a.m. Eastern Time at the Harvard Club in New York City. The event will feature presentations from the company's senior management team, who will discuss Ligand's corporate strategy, investment activities, royalty portfolio, and long-term financial projections. Investors and interested parties can access the event through a live webcast via Ligand's Investor Relations website at investor.ligand.com. Additional details, including dial-in information and a comprehensive agenda, will be provided as the event date approaches.
Ligand Pharmaceuticals (NASDAQ: LGND) ha annunciato che il 9 dicembre 2025 alle 10:00 ora orientale terrà un Investor Day presso l'Harvard Club di New York. L'evento includerà presentazioni del team di alta dirigenza dell'azienda, che illustrerà la strategia aziendale di Ligand, le attività di investimento, il portafoglio di royalty e le proiezioni finanziarie a lungo termine. Investitori e interessati potranno seguire l'evento in diretta streaming tramite il sito web delle Relazioni con gli Investitori di Ligand all'indirizzo investor.ligand.com. Ulteriori dettagli, comprese le informazioni per la chiamata e un'agenda completa, saranno forniti man mano che si avvicinerà la data dell'evento.
Ligand Pharmaceuticals (NASDAQ: LGND) ha anunciado que el 9 de diciembre de 2025 a las 10 a.m. hora del este realizará un Investor Day en el Harvard Club de Nueva York. El evento contará con presentaciones del equipo directivo senior de la compañía, quienes discutirán la estrategia corporativa de Ligand, sus actividades de inversión, la cartera de regalías y las proyecciones financieras a largo plazo. Los inversores y partes interesadas podrán acceder al evento mediante una transmisión en vivo a través del sitio web de Relaciones con Inversores de Ligand en investor.ligand.com. Se proporcionarán detalles adicionales, incluyendo información para llamadas y una agenda completa, a medida que se acerque la fecha del evento.
Ligand Pharmaceuticals (NASDAQ: LGND)는 2025년 12월 9일 동부 시간 오전 10시에 뉴욕 하버드 클럽에서 투자자 설명회를 개최할 계획이라고 발표했습니다. 이번 행사에서는 회사의 고위 경영진이 Ligand의 기업 전략, 투자 활동, 로열티 포트폴리오 및 장기 재무 전망에 대해 발표할 예정입니다. 투자자 및 관심 있는 분들은 Ligand 투자자 관계 웹사이트 investor.ligand.com을 통해 라이브 웹캐스트로 행사를 시청할 수 있습니다. 행사 날짜가 가까워지면 전화 접속 정보와 종합 일정 등 추가 세부 정보가 제공될 예정입니다.
Ligand Pharmaceuticals (NASDAQ : LGND) a annoncé qu'elle organiserait une journée investisseurs le 9 décembre 2025 à 10h00, heure de l'Est, au Harvard Club de New York. L'événement comprendra des présentations de l'équipe de direction de l'entreprise, qui abordera la stratégie d'entreprise de Ligand, ses activités d'investissement, son portefeuille de redevances et ses projections financières à long terme. Les investisseurs et parties intéressées pourront suivre l'événement en direct via un webcast accessible depuis le site Relations Investisseurs de Ligand à investor.ligand.com. Des informations complémentaires, incluant les détails pour la connexion téléphonique et un programme complet, seront communiquées à l'approche de la date de l'événement.
Ligand Pharmaceuticals (NASDAQ: LGND) hat angekündigt, am 9. Dezember 2025 um 10 Uhr Eastern Time einen Investorentag im Harvard Club in New York City abzuhalten. Bei der Veranstaltung wird das Führungsteam des Unternehmens Präsentationen halten, in denen sie Ligands Unternehmensstrategie, Investitionstätigkeiten, Lizenzportfolio und langfristige Finanzprognosen erläutern. Investoren und Interessierte können die Veranstaltung über einen Live-Webcast auf der Investor-Relations-Website von Ligand unter investor.ligand.com verfolgen. Weitere Details, einschließlich Einwahlinformationen und einer ausführlichen Agenda, werden mit Annäherung an den Veranstaltungstermin bereitgestellt.
Positive
  • None.
Negative
  • None.

JUPITER, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor Day in New York City on Tuesday, December 9, 2025 at 10 a.m. Eastern Time at the Harvard Club.

The event will include presentations from Ligand’s senior management team highlighting the company’s strategy, investment activity, royalty portfolio, and long-term financial outlook. A live webcast of the event will be accessible through Ligand’s Investor Relations website at investor.ligand.com. A detailed agenda, including dial-in information, will be provided closer to the event.

About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. We operate two infrastructure-light royalty generating technology IP platform technologies. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Our NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. We have established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com. Follow Ligand on X and LinkedIn.

We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts.

Contacts
Investors:
Melanie Herman
investors@ligand.com
(858) 550-7761

Media:
Kellie Walsh
media@ligand.com
(914) 315-6072


FAQ

When is Ligand Pharmaceuticals (LGND) hosting its 2025 Investor Day?

Ligand Pharmaceuticals will host its Investor Day on Tuesday, December 9, 2025, at 10 a.m. Eastern Time at the Harvard Club in New York City.

What topics will be covered at LGND's 2025 Investor Day?

The event will cover Ligand's corporate strategy, investment activities, royalty portfolio, and long-term financial outlook through presentations from the senior management team.

How can investors access Ligand's 2025 Investor Day event?

Investors can access the event through a live webcast on Ligand's Investor Relations website at investor.ligand.com. Dial-in information will be provided closer to the event date.

Where will Ligand's 2025 Investor Day be held?

Ligand's Investor Day will be held at the Harvard Club in New York City.
Ligand Pharma

NASDAQ:LGND

LGND Rankings

LGND Latest News

LGND Stock Data

2.00B
18.83M
2.06%
98.51%
4.05%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO